Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Status
Active
Cancer Type
Kidney Cancer
Unknown Primary
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04736706
Protocol IDs
6482-012 (primary)
MK-6482-012
NCI-2021-05629
2020-002216-52
Study Sponsor
Merck Sharp & Dohme LLC

Summary

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus
belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab
plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell
carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to
pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall
survival (OS), in advanced ccRCC participants and (2) pembrolizumab/quavonlimab plus
lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in
advanced ccRCC participants.

Eligibility

  1. Has histologically confirmed diagnosis of RCC with clear cell component
  2. Has received no prior systemic therapy for advanced ccRCC
  3. Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib
  4. Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last
  5. Has adequately controlled blood pressure with or without antihypertensive medications
  6. Has adequate organ function
  7. Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.